Dr. Siti Aishah Hassan

Dr. Siti Aishah Hassan is a consultant medical oncologist at Prince Court Medical Centre in Kuala Lumpur — one of Malaysia's most prestigious private hospitals and a leading centre for cancer care in Southeast Asia. With 20 years of oncology practice, Dr. Hassan provides comprehensive medical oncology care for patients with haematological malignancies, breast cancer, colorectal cancer, and other solid tumours.

Malaysia has invested substantially in cancer infrastructure, with hospitals such as Prince Court offering PET-CT imaging, genomic tumour profiling, and access to international clinical trials. The country attracts medical tourists from Indonesia, Brunei, Myanmar, Bangladesh, and the Middle East, drawn by its English-language medical services, relatively lower treatment costs compared to Singapore or Australia, and high-quality specialist care.

Dr. Hassan's clinical philosophy emphasises personalised treatment planning that integrates molecular tumour characteristics with patient preferences, co-morbidities, and quality-of-life goals. She is a strong advocate for evidence-based immunotherapy and targeted therapy, and keeps her practice aligned with ESMO and ASCO guidelines. She is trilingual in English, Bahasa Malaysia, and Mandarin — an asset in a culturally diverse patient population.

Dr. Hassan graduated with her MBBS from the University of Malaya, the premier research university in Malaysia. She completed Internal Medicine residency, earning her MMed (Internal Medicine), and subsequently passed the MRCP (UK) examination — an internationally benchmarked credential in internal medicine. She completed a formal Fellowship in Medical Oncology at the University of Malaya Medical Centre (UMMC), where she trained in the management of both solid tumours and haematological malignancies.

She has undertaken observership training at oncology centres in the United Kingdom and Australia, and attends ESMO and ASCO annual meetings regularly to update her clinical practice with the latest evidence.

Dr. Hassan's clinical expertise spans medical oncology for both solid tumours and blood cancers. In haematological malignancies, she manages Hodgkin lymphoma, non-Hodgkin lymphoma (DLBCL, follicular lymphoma), chronic lymphocytic leukaemia (CLL), and multiple myeloma, using chemotherapy, targeted therapy (BTK inhibitors, anti-CD20 monoclonal antibodies), and immunomodulatory agents.

In solid tumours, she manages breast cancer across all molecular subtypes — hormone receptor-positive (aromatase inhibitor and CDK4/6 inhibitor-based regimens), HER2-positive (trastuzumab combinations), and triple-negative (chemotherapy and immunotherapy). She treats colorectal cancer with FOLFOX/FOLFIRI regimens combined with bevacizumab or anti-EGFR agents where appropriate. For lung cancer and nasopharyngeal carcinoma — tumours with particularly high incidence in the Southeast Asian population — she uses platinum-based chemotherapy and immunotherapy.

She participates in the hospital's multidisciplinary tumour board and coordinates care with surgical oncology and radiation oncology.

Prince Court Medical Centre in Kuala Lumpur is one of Southeast Asia's most internationally oriented hospitals, with a dedicated International Patient Centre that assists patients from Indonesia, Brunei, Bangladesh, and the Middle East with appointment coordination, accommodation, medical visas, and translation services. The hospital is JCI-accredited and uses the same international treatment guidelines as hospitals in Europe and the USA.

Dr. Hassan offers video consultations for international patients to review pathology reports, imaging, and genomic profiling results remotely before deciding on treatment in Kuala Lumpur. She consults in English, Bahasa Malaysia, and Mandarin. Malaysia's relatively affordable treatment costs — significantly lower than Singapore or Australia — make it an attractive regional cancer care destination.

Dr. Hassan is an active member of the Malaysian Oncological Society (MOS) and contributes to continuing medical education in oncology across Malaysia. Her MRCP (UK) credential reflects British standard clinical training. She has been recognised by Prince Court Medical Centre for clinical excellence in oncology care and has contributed to faculty development at the University of Malaya's oncology training programme. She presents regularly at the Malaysian Oncological Society Annual Scientific Meeting.